Trial Profile
A Phase 1, Open-label, Dose Finding Study of CC-93269, a BCMA X CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 22 Mar 2024
Price :
$35
*
At a glance
- Drugs Alnuctamab (Primary) ; Alnuctamab (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; First in man
- Sponsors Celgene Corporation
- 12 Dec 2023 Results assessing updated data for SC ALNUC in patients with relapsed/refractory multiple myeloma treated in the phase 1 study, were presented at the 65th American Society of Hematology Annual Meeting and Exposition.
- 11 Dec 2023 According to a Bristol-Myers Squibb media release, results from this trial were presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition 2023.
- 11 Dec 2023 Results presented in the Bristol-Myers Squibb Media Release.